Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QASED
- Development stage
- Unknown
- Lead developer
- Ocubio
- Administration
- Ophthalmic
01
Overview
QASED (Qualified Autologous Serum Eye Drops) is a personalized, blood-derived biologic therapy developed by Ocubio for the treatment of ocular surface diseases, such as dry eye disease. Based on a proprietary manufacturing protocol developed at the Bascom Palmer Eye Institute, QASED is prepared from a patient's own blood serum, which naturally contains essential proteins and growth factors (including albumin, fibronectin, vitamin A, epidermal growth factor, and transforming growth factor-beta) that mimic natural tears. Unlike conventional autologous serum eye drops that require constant freezing, QASED features room-temperature stability for up to one week after opening and is delivered in single-week vials.
- Brand names
- QASED
- Other names
- Qualified Autologous Serum Eye DropsqASED
Beyond the preview
Go deeper on QASED.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QASED.